Free Trial

iCAD Q1 2024 Earnings Report

iCAD logo
$1.83 +0.06 (+3.39%)
(As of 12/20/2024 05:16 PM ET)

iCAD Earnings Headlines

Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
US Penny Stocks To Watch In December 2024
See More iCAD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iCAD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iCAD and other key companies, straight to your email.

About iCAD

iCAD (NASDAQ:ICAD) engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

View iCAD Profile

More Earnings Resources from MarketBeat

Upcoming Earnings